Lumida
/BBNX
⌘K
Beta Bionics Inc

Beta Bionics Inc

BBNX
$17.29USD↑+2.31%+0.39 today

MARKET CAP

770.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$16 – $18

52W RANGE

$9
$33

AI Summary

Stalk
StalkMedium

BBNX remains in a Stage 2 advancing regime with clear higher highs and higher lows supported by rising EMAs. Price is extended into overbought territory near prior resistance and shows minor exhaustion signals, making short-term timing unfavorable. We defer entries and look for a selective pullback into the rising 9/21 EMA support zone. A decisive close below the 21 EMA on increased volume would invalidate the medium-term bullish bias and require reassessment.

  • ↑Q1 net sales reached $27.6M, up 57% YoY, driving revenue momentum.
  • ↑Gross margin expanded to 59.5%, up ~400bps YoY via high-margin pharmacy channel.
  • ↓Operating expenses rose to $40.7M, a 47% YoY increase, pressuring cash burn.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Beta Bionics, Inc. (NASDAQ: BBNX) is a pioneering player in the diabetes management sector, focusing on innovative insulin delivery solutions through its fully automated islet device. The company aims to revolutionize diabetes care with its advanced technologies, positioning itself at the intersection of healthcare and technology. With an emphasis on developing pharmacy channel access and enhancing product offerings like the Mint patch pump, Beta Bionics is well-poised for growth in the burgeoning diabetes management market.

Bull says

  • ↑Q1 net sales reached $27.6M, up 57% YoY, driving revenue momentum.
  • ↑Gross margin expanded to 59.5%, up ~400bps YoY via high-margin pharmacy channel.
  • ↑2026 revenue guidance raised to $131–136M, reflecting stronger growth outlook.
  • ↑Adding 20 new sales territories in 2026 to boost market penetration.
  • ↑Mint patch pump slated for end-2027 launch, a major future catalyst.
  • ↑High institutional ownership and robust trading liquidity signal investor confidence.

Bear says

  • ↓Operating expenses rose to $40.7M, a 47% YoY increase, pressuring cash burn.
  • ↓Ongoing FDA warning letter remediation risks delaying device clearances.
  • ↓Intense competition in insulin delivery may pressure pricing and margins.
  • ↓Pharmacy channel dependency (37–39% new starts) exposes revenue to reimbursement shifts.
  • ↓Weak profitability metrics and elevated leverage heighten sensitivity to market swings.
  • ↓Regulatory and reimbursement policy changes could undermine growth assumptions.

Investment themes with BBNX

Medical Devices↑ +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-23-2026neutral

Transcript signals

Bull points

  • Our Q1 performance exceeded our expectations across the board.
  • Q1 revenue saw modest contribution from pharmacy and DME stocking, but the stocking benefit in Q1 declined relative to Q4 in both channels.
  • A high 30s percentage of our new patient starts in Q1 accessed islet through the pharmacy channel. The increase compared to the prior quarter exceeded our expectations.

Bear points

  • New patient starts declined more than 10%, but less than 20% compared to Q4 2025, consistent with our expectations given typical seasonal demand patterns from Q4 to Q1.
  • Regarding the warning letter, the company is continuing to take this matter very seriously.
  • Regarding the warning letter, the company is continuing to take this matter very seriously.
Read full transcript analysis ›